BRPI0519209A2 - compostos orgçnicos - Google Patents
compostos orgçnicosInfo
- Publication number
- BRPI0519209A2 BRPI0519209A2 BRPI0519209-9A BRPI0519209A BRPI0519209A2 BR PI0519209 A2 BRPI0519209 A2 BR PI0519209A2 BR PI0519209 A BRPI0519209 A BR PI0519209A BR PI0519209 A2 BRPI0519209 A2 BR PI0519209A2
- Authority
- BR
- Brazil
- Prior art keywords
- mono
- organic compounds
- diaspartate
- diglutamate
- disuccinate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0428151.5A GB0428151D0 (en) | 2004-12-22 | 2004-12-22 | Organic compounds |
| PCT/EP2005/013703 WO2006066868A2 (en) | 2004-12-22 | 2005-12-20 | Sustained release formulation comprising bisphosphonate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0519209A2 true BRPI0519209A2 (pt) | 2009-01-06 |
Family
ID=34113101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519209-9A BRPI0519209A2 (pt) | 2004-12-22 | 2005-12-20 | compostos orgçnicos |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20100029550A1 (ru) |
| EP (1) | EP1830806B1 (ru) |
| JP (1) | JP4977622B2 (ru) |
| KR (1) | KR101335757B1 (ru) |
| CN (1) | CN101072551B (ru) |
| AR (1) | AR051803A1 (ru) |
| AU (1) | AU2005318454B2 (ru) |
| BR (1) | BRPI0519209A2 (ru) |
| CA (1) | CA2585116C (ru) |
| ES (1) | ES2515097T3 (ru) |
| GB (1) | GB0428151D0 (ru) |
| GT (1) | GT200500358A (ru) |
| MX (1) | MX2007007572A (ru) |
| PE (1) | PE20060769A1 (ru) |
| PL (1) | PL1830806T3 (ru) |
| PT (1) | PT1830806E (ru) |
| RU (1) | RU2395274C2 (ru) |
| TW (1) | TW200637612A (ru) |
| WO (1) | WO2006066868A2 (ru) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| EP2067786A1 (en) | 2007-12-07 | 2009-06-10 | ITALFARMACO S.p.A. | Novel non selective analogs of somatostatin |
| CA2702940C (en) | 2007-12-03 | 2016-09-13 | Andrea Vitali | New non-selective somatostatin analogues |
| EA023128B1 (ru) | 2010-01-13 | 2016-04-29 | Ипсен Фарма С.А.С. | Способ получения инъекционной фармацевтической композиции с замедленным высвобождением ланреотида |
| US8535544B2 (en) | 2010-07-26 | 2013-09-17 | International Business Machines Corporation | Structure and method to form nanopore |
| WO2013131879A1 (en) | 2012-03-07 | 2013-09-12 | Novartis Ag | New application for pasireotide |
| EP2823808A1 (en) * | 2013-07-09 | 2015-01-14 | Ipsen Pharma S.A.S. | Pharmaceutical composition for a sustained release of lanreotide |
| US11278507B2 (en) | 2016-09-06 | 2022-03-22 | Monell Chemical Senses Center | Method of regulating immunity in the intestines |
| AU2018230429B2 (en) * | 2017-03-09 | 2023-06-15 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor modulators in the treatment of catecholamine-secreting tumors |
| GR1009814B (el) * | 2019-07-29 | 2020-09-11 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει ενα πεπτιδιο αναλογο σωματοστατινης |
| AU2022390573A1 (en) * | 2021-11-22 | 2024-05-16 | SpecGx LLC | Injectable sustained release pharmaceutical composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE14226T1 (de) * | 1981-12-24 | 1985-07-15 | Ciba Geigy Ag | Cyclische octapeptide und pharmazeutische praeparate davon, sowie verfahren zur herstellung derselben und ihre anwendung. |
| PH30995A (en) * | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| MY147327A (en) | 1995-06-29 | 2012-11-30 | Novartis Ag | Somatostatin peptides |
| GB9601120D0 (en) | 1996-01-19 | 1996-03-20 | Sandoz Ltd | Organic compounds |
| US20020111603A1 (en) * | 1996-12-02 | 2002-08-15 | Societe De Conseils De Recherches Et D'application | Device for local administration of solid or semi-solid formulations and delayed-release formulations for proposal parental administration and preparation process |
| ATE318580T1 (de) | 1996-12-20 | 2006-03-15 | Alza Corp | Gelzusammensetzungen und verfahren |
| FR2776520B1 (fr) * | 1998-03-25 | 2000-05-05 | Sod Conseils Rech Applic | Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| US7098305B2 (en) * | 2001-09-06 | 2006-08-29 | Ardana Bioscience Limited | Sustained release of microcrystalline peptide suspensions |
| JP2005525374A (ja) * | 2002-03-04 | 2005-08-25 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | 担体ペプチドを含有する持続放出ドラッグ製剤 |
| GB0300095D0 (en) | 2003-01-03 | 2003-02-05 | Novartis Ag | Organic compounds |
| GB0428151D0 (en) * | 2004-12-22 | 2005-01-26 | Novartis Ag | Organic compounds |
| ES2399651T3 (es) * | 2008-07-08 | 2013-04-02 | Novartis Ag | Utilización de pasireotida para el tratamiento de la hipoglucemia hiperinsulenémica endógena |
-
2004
- 2004-12-22 GB GBGB0428151.5A patent/GB0428151D0/en not_active Ceased
-
2005
- 2005-12-07 GT GT200500358A patent/GT200500358A/es unknown
- 2005-12-16 PE PE2005001479A patent/PE20060769A1/es not_active Application Discontinuation
- 2005-12-20 AR ARP050105373A patent/AR051803A1/es not_active Application Discontinuation
- 2005-12-20 US US11/721,082 patent/US20100029550A1/en not_active Abandoned
- 2005-12-20 CN CN2005800416891A patent/CN101072551B/zh active Active
- 2005-12-20 EP EP05804975.0A patent/EP1830806B1/en active Active
- 2005-12-20 PL PL05804975T patent/PL1830806T3/pl unknown
- 2005-12-20 CA CA2585116A patent/CA2585116C/en not_active Expired - Fee Related
- 2005-12-20 KR KR1020077014069A patent/KR101335757B1/ko not_active IP Right Cessation
- 2005-12-20 RU RU2007128101/15A patent/RU2395274C2/ru not_active IP Right Cessation
- 2005-12-20 PT PT58049750T patent/PT1830806E/pt unknown
- 2005-12-20 AU AU2005318454A patent/AU2005318454B2/en not_active Ceased
- 2005-12-20 ES ES05804975.0T patent/ES2515097T3/es active Active
- 2005-12-20 JP JP2007547318A patent/JP4977622B2/ja active Active
- 2005-12-20 WO PCT/EP2005/013703 patent/WO2006066868A2/en active Application Filing
- 2005-12-20 MX MX2007007572A patent/MX2007007572A/es active IP Right Grant
- 2005-12-20 BR BRPI0519209-9A patent/BRPI0519209A2/pt not_active IP Right Cessation
- 2005-12-21 TW TW094145646A patent/TW200637612A/zh unknown
-
2014
- 2014-04-30 US US14/265,605 patent/US9303067B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP1830806A2 (en) | 2007-09-12 |
| PT1830806E (pt) | 2014-11-24 |
| CA2585116C (en) | 2014-05-20 |
| JP2008524290A (ja) | 2008-07-10 |
| GT200500358A (es) | 2006-08-07 |
| WO2006066868A2 (en) | 2006-06-29 |
| GB0428151D0 (en) | 2005-01-26 |
| AR051803A1 (es) | 2007-02-07 |
| US9303067B2 (en) | 2016-04-05 |
| PL1830806T3 (pl) | 2015-03-31 |
| TW200637612A (en) | 2006-11-01 |
| ES2515097T3 (es) | 2014-10-29 |
| KR101335757B1 (ko) | 2013-12-02 |
| AU2005318454B2 (en) | 2009-08-20 |
| MX2007007572A (es) | 2007-07-24 |
| CA2585116A1 (en) | 2006-06-29 |
| US20100029550A1 (en) | 2010-02-04 |
| AU2005318454A1 (en) | 2006-06-29 |
| EP1830806B1 (en) | 2014-09-03 |
| CN101072551B (zh) | 2013-04-24 |
| RU2007128101A (ru) | 2009-01-27 |
| WO2006066868A3 (en) | 2006-10-12 |
| US20150038414A1 (en) | 2015-02-05 |
| PE20060769A1 (es) | 2006-09-28 |
| JP4977622B2 (ja) | 2012-07-18 |
| CN101072551A (zh) | 2007-11-14 |
| RU2395274C2 (ru) | 2010-07-27 |
| KR20070090942A (ko) | 2007-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0519209A2 (pt) | compostos orgçnicos | |
| MX338338B (es) | Composiciones y metodos utiles para el tratamiento de enfermedades respiratorias. | |
| ECSP066477A (es) | Composición farmacéutica que comprende ácido (2r)-2-propiloctanoico como un ingrediente activo | |
| PE20130578A1 (es) | Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa | |
| NZ597260A (en) | Formulations for parenteral delivery of compounds and uses thereof comprising methylnaltrexone | |
| NZ597237A (en) | Sublingual apomorphine | |
| MX2010007523A (es) | Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer. | |
| NZ607595A (en) | A process for concentration of a polypeptide | |
| TNSN07419A1 (en) | Methods for treating drug resistant cancer | |
| RS51688B (en) | METHOTREXATE CONCENTRATED SOLUTIONS | |
| ATE419842T1 (de) | Abgabevehikel mit nanoteilchen | |
| SG162744A1 (en) | Stable active ingredient complex of salts of the o-acetylsalicylic acid with basic amino acids and glycine | |
| PE20141539A1 (es) | Una nueva composicion terapeutica que contiene apomorfina como principio activo | |
| WO2006131923A3 (en) | Novel salts of conjugated psychotropic drugs and processes of preparing same | |
| NI200600146A (es) | Composición farmacéutica de vinflunina para administración parenteral, proceso de preparación y su uso | |
| DE60116483D1 (de) | Gelartige pharmazeutische zusammensetzung zur subcutanen anwendung enthaltend bisphosphonsäuren oder deren salze | |
| MX2007009312A (es) | Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables. | |
| WO2008001204A3 (en) | Transdermal compositions of pramipexole having enhanced permeation properties | |
| AR074724A1 (es) | Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno | |
| BRPI0800744A2 (pt) | composiÇço de inibiÇço de infecÇço por salmonella para pinto e mÉtodo de inibiÇço de infecÇço por salmonella em pintos | |
| WO2006138589A3 (en) | Opioid receptor ligands | |
| UA91136C2 (ru) | Системы, фармацевтическая композиция на его основе и способ ее применения | |
| TW200727904A (en) | Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine | |
| PL1620072T3 (pl) | Zawierająca cynk kompozycja o przedłużonym uwalnianiu, produkt leczniczy i sposób jego wytwarzania | |
| AR124399A2 (es) | Formulaciones estables para la administración intratecal de iduranato-2-sulfatasa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |